Drug Profile

XBIO 015

Alternative Names: XBIO-015

Latest Information Update: 22 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xenetic Biosciences
Developer PeriNess; Xenetic Biosciences
Class Antineoplastics; Endodeoxyribonucleases; Recombinant proteins
Mechanism of Action Extracellular trap inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Pancreatic cancer
Clinical Phase Unknown B-cell lymphoma
Preclinical Colorectal cancer; Solid tumours

Most Recent Events

04 Jun 2026 Clinical trials in B-cell lymphoma (Combination therapy) in Israel (IV)
04 Jun 2026 Israel Ministry of Health approves IND application for XBIO 015 in B-cell lymphoma (Combination therapy)
19 Dec 2025 Xenetic Biosciences extended its collaboration with The Scripps Research Institute

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com